### Inhaled nitric oxide (iNO) therapy in NICU for Pulmonary Hypertension

**Sites where Local Guideline applies**

This Local Guideline applies to:

1. Adults  
   - No
2. Children up to 16 years  
   - No
3. Neonates – less than 29 days  
   - Yes

**Target audience**  
NICU clinical staff, which provide care to neonatal patients

**Description**  
The guideline provides information about neonatal assessment to ensure escalation of treatment occurs as necessary

**National Standard**  
Standard 4 Medication Safety

**Go to Guideline**

**Keywords**  
calibration, half-life, INOMAX, nitric oxide, persistent pulmonary hypertension of the newborn, PPHN, vasodilator

**Keyword**  
persistent pulmonary hypertension of the newborn (PPHN)

**Document registration number**  
JHCH_NICU_12.08

**Replaces existing document?**  
Yes

**Registration number and dates of superseded documents**  
NITRIC OXIDE (iNO) THERAPY in NICU for Persistent Pulmonary Hypertension of the Newborn  
26/05/2014

**Related Legislation, Australian Standard, NSW Ministry of Health Policy Directive or Guideline, National Safety and Quality Health Service Standard (NSQHSS) and/or other, HNE Health Document, Professional Guideline, Code of Practice or Ethics:**

- NSW Health Policy PD2013_043 Medication handling in NSW Public Health Facilities
- NSW Health Policy Directive PD2017_032Clinical Procedure Safety

**Prerequisites (if required)**  
N/A

**Local Guideline note**  
This document reflects what is currently regarded as safe and appropriate practice. The guideline section does not replace the need for the application of clinical judgment in respect to each individual patient but the procedure/s require mandatory compliance. If staff believe that the procedure/s should not apply in a particular clinical situation they must seek advice from their unit manager/delegate and document the variance in the patients’ health record.

**Position responsible for the Local Guideline and authorised by**  
Pat Marks. General Manager / Director of Nursing CYPFS

**Contact person**  
Jennifer Ormsby NICU Guideline Coordinator NICU JHCH

**Contact details**  
Jennifer.Ormsby@hnehealth.nsw.gov.au  Phone 02 4985 5304

**Date authorised**  
10th September 2017

**This document contains advice on therapeutics**  
Yes Approval gained from Local Quality Use of Medicines Committee on July 2017

**Issue date**  
15th November 2017

**Review date**  
10th September 2020
Inhaled nitric oxide (iNO) therapy in NICU for Pulmonary Hypertension JHCH_NICU_12.08

Note: Over time, links in this document may cease working. Where this occurs please source the document in the PPG Directory at: http://ppg.hne.health.nsw.gov.au/

RISK STATEMENT

This local guideline has been developed to provide guidance to clinical staff in NICU when nitric oxide is ordered for an infant in NICU. It ensures that the risks of harm to infants, staff and families during set-up and administration are identified and managed.

Any unplanned event resulting in, or with the potential for injury, damage or other loss to infants/ staff/ families as a result of this procedure must be reported through the Incident Information management System and managed in accordance with the Ministry of Health Policy Directive: Incident management PD2014_004. This would include unintended injury that results in disability, death or prolonged hospital stay.

Risk Category: Clinical Care & Patient Safety

Outcomes

1. To deliver safe and effective inhaled nitric oxide (iNO) to the infant

2. Parents informed of therapy and infant’s clinical progress

3. Staff to gain understanding of pathophysiology of persistent pulmonary hypertension and the potential benefits of iNO treatment

ABBREVIATIONS & GLOSSARY

<table>
<thead>
<tr>
<th>Abbreviation/Word</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPAP</td>
<td>Continuous Positive Airway Pressure</td>
</tr>
<tr>
<td>INOmax DSir Plus</td>
<td>Delivery system for nitric oxide</td>
</tr>
<tr>
<td>ECMO</td>
<td>Extracorporeal membrane oxygenation</td>
</tr>
<tr>
<td>ETT</td>
<td>Endotracheal tube</td>
</tr>
<tr>
<td>FiO₂</td>
<td>Fractional concentration of inspired oxygen</td>
</tr>
<tr>
<td>FRC</td>
<td>Functional residual capacity</td>
</tr>
<tr>
<td>HFNC</td>
<td>High flow nasal cannula</td>
</tr>
<tr>
<td>HFOV</td>
<td>High-frequency oscillatory ventilation</td>
</tr>
<tr>
<td>IR</td>
<td>Infrared</td>
</tr>
<tr>
<td>IVH</td>
<td>intraventricular haemorrhage</td>
</tr>
<tr>
<td>Low Cal</td>
<td>Low-range calibration</td>
</tr>
<tr>
<td>MAP</td>
<td>Mean airway pressure</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Met Hb</td>
<td>Methaemoglobin</td>
</tr>
<tr>
<td>MO</td>
<td>Medical Officer</td>
</tr>
<tr>
<td>NICU</td>
<td>Neonatal Intensive Care Unit</td>
</tr>
<tr>
<td>NO/INO/NO₂</td>
<td>Nitric oxide/inhaled nitric oxide/ nitrogen dioxide</td>
</tr>
<tr>
<td>NOS</td>
<td>Nitric oxide synthase</td>
</tr>
<tr>
<td>OI</td>
<td>Oxygen Index</td>
</tr>
<tr>
<td>PaCO₂</td>
<td>Arterial partial pressure of carbon dioxide</td>
</tr>
<tr>
<td>PaO₂</td>
<td>Arterial partial pressure of oxygen</td>
</tr>
<tr>
<td>PAP</td>
<td>Pulmonary Arterial Pressure</td>
</tr>
<tr>
<td>PIP/PEEP</td>
<td>Peak inspiratory pressure/Positive End-Expiratory Pressure</td>
</tr>
<tr>
<td>PPE</td>
<td>Personal Protective Equipment</td>
</tr>
<tr>
<td>PPHN</td>
<td>Persistent pulmonary hypertension of the newborn</td>
</tr>
<tr>
<td>ppm</td>
<td>Parts per million</td>
</tr>
<tr>
<td>PPROM</td>
<td>Preterm premature rupture of membranes</td>
</tr>
<tr>
<td>psi</td>
<td>Pounds per square inch</td>
</tr>
<tr>
<td>RDS</td>
<td>Respiratory Distress Syndrome</td>
</tr>
<tr>
<td>SAP</td>
<td>Systemic Arterial Pressure</td>
</tr>
<tr>
<td>TA</td>
<td>Technical Assistant</td>
</tr>
<tr>
<td>WOW</td>
<td>Workstation on wheels</td>
</tr>
</tbody>
</table>
GUIDELINE

This Guideline does not replace the need for the application of clinical judgment in respect to each individual patient.

NITRIC OXIDE (iNO) THERAPY in NICU One Page Summary and Checklist

(Ctrl+Click on Coloured words to jump to that section)

Section 1 Indications for prescribing nitric oxide

Aims

Summary

Pulmonary Hypertension

Use of iNO for Pulmonary Hypertension

Treatment of Pulmonary Hypertension

A. Optimise lung distention

B. Lower pulmonary arterial pressure (PAP)

C. Supporting cardiovascular function

References

Section 2 Inomax DSIR+ setup and testing

INOMax DSIR Plus setup

INOMax DSIR Plus Pre-use tests

Step 1 High pressure leak test

Step 2 Manual purge and alarm verification

Step 3 Backup delivery test

Step 4 Performance test

Step 5 INOblender test

Section 3 Changing the NO cylinder

Section 4 Management

Management of infant receiving iNO

Monitoring & precautions when using iNO therapy

Appendix 1 Connections & Setup for iNO via HP circuit

Appendix 2 Connection to the Fisher &Paykel bubble CPAP circuit

Appendix 3 Connections and setup for iNO via HP circuit

Appendix 4 Connection to Fisher & Paykel bubble CPAP

Appendix 5 Manual Pre-Use Checkout

Appendix 6 INOMax DSIR Plus Handover Circuit Checklist

Section 1
Use of inhaled nitric oxide (iNO) for pulmonary hypertension

Aims:
1. To provide guidance for appropriate use of iNO in the NICU
2. To optimise patient’s clinical condition before starting iNO
3. To provide iNO in a manner that is safe, cost-effective & beneficial to patient outcomes
4. To establish suitable criteria to help assess patient responsiveness to iNO & it’s weaning

Summary
In term or near-term infants with significant hypoxic respiratory failure defined as PaO₂ < 100 mmHg on FiO₂ > 0.8 and/or Oxygenation Index (OI) between 15 and 25, start iNO at 20 ppm. Document respiratory, blood gas and cardiovascular parameters at start and after 15 to 30 minutes of iNO (use sticker).

<table>
<thead>
<tr>
<th></th>
<th>At start</th>
<th>After 15–30 minutes of iNO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean airway pressure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FiO₂</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SpO₂ (post-ductal)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial PaO₂ (if available)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OI (= MAP x FiO₂ / PaO₂)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic blood pressure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Echo R-to-L shunt % (if available)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Positive response:** Rise in post-ductal PaO₂ ≥ 20 mmHg or SpO₂ by ≥ 10% or able to drop FiO₂ by at least 0.2. On Echocardiograph echocardiography assessment, significant reduction in R-toL shunting and improved left ventricular filling.

**Partial response:** Rise in post-ductal PaO₂ by 10–12 mmHg or SpO₂ by 5–10% or able to drop FiO₂ by 0.1–0.2 or reduction in R-to-L shunt on echocardiography.
**Negative response:** Either no change or a rise in post-ductal PaO\(_2\) of < 10 mmHg or SpO\(_2\) by < 5% or only able to drop FiO\(_2\) by < 0.1, or no reduction in R-to-L shunt on echocardiography.

Continue iNO if responder or partial responder; stop if non-responder.

| Initiate weaning when FiO\(_2\) is less than 0.4 for 6–12 hours. Wean iNO by 5 ppm every 2 hours until down to 5 ppm, leave on 5 ppm for 2 hours and then wean by 1 ppm every 2 hours. |

Inhaled nitric oxide (iNO) therapy in NICU for Pulmonary Hypertension JHCH_NICU_12.08

Inhaled NO can be provided with any form of respiratory support (mechanical ventilation, CPAP, HFNC, nasal cannula).

In preterm infants with evidence of lung hypoplasia and pulmonary hypertension due to prolonged PPROM, start iNO 10-20 ppm early and monitor response.

In preterm infants with hypoxic respiratory failure due to other reasons, it is not recommended to start iNO without documenting significant pulmonary hypertension on echocardiography.

**Definitions**

Persistent pulmonary hypertension of the newborn (PPHN): When the normal cardiopulmonary transition fails to occur and there is increased pulmonary vascular resistance and the presence of a right-left shunt at the foramen ovale and/or ductus arteriosus level. The patient may or may not have pulmonary hypertension.

Pulmonary hypertension (PH): Increased pulmonary arterial pressure, where the mean pulmonary arterial pressure > ½ mean systemic arterial pressure. It is clinically significant when it produces hypoxia.

**Pulmonary hypertension of the newborn, background**

PH can be caused by a broad range of pulmonary and non-pulmonary diseases. The main physiological triggers for PH are (alveolar) hypoxia and acidosis, but PH can also be triggered by other factors such as endotoxins and inflammatory signals. Hypoxic pulmonary vasoconstriction is a physiological response of the body to improve systemic hypoxia, but this process can fail during severe and/or prolonged hypoxia and acidosis. Developmental changes to the pulmonary parenchyma and vasculature (e.g. extreme prematurity, lung hypoplasia, diaphragmatic hernia, chronic lung disease) can also alter this physiological response.

With PH, the right ventricle has to work against a high pulmonary vascular resistance (PVR) to have blood flow through the pulmonary circulation. Blood will try to flow through the path of least resistance, in the newborn represented by the fetal shunts (foramen ovale, ductus arteriosus). Those shunts will increase the amount of blood flowing right-to-left, further diminishing blood flow through the lungs and thus contribute to the persistent hypoxia. The ongoing hypoxia and acidosis, together with closure of the fetal shunts, will eventually lead to right ventricular failure.
PH is a dynamic process in newborns. Its clinical severity will depend on the condition at birth, the extent of the developmental changes, the onset and degree of cardiac dysfunction and how shunts can offer pressure offload for the right ventricle.

Treatment of PH includes a range of measures to address the above mentioned pathophysiology, including the use of inhaled nitric oxide (iNO).

**Use of iNO for pulmonary hypertension**

This guideline will focus on the use of inhaled nitric oxide (iNO) as pulmonary vasodilator therapy, but it is important to realise that additional steps are needed to control PH and optimise the efficacy of iNO.

Nitric oxide (NO) is an endogenous mediator of smooth muscle relaxation. NO is rapidly inactivated once it combines with haemoglobin in the blood stream. Due to this rapid inactivation, inhaled NO (iNO) can be administered exogenously as a selective pulmonary vasodilator. When NO reaches the capillary bed of the lungs, it is inactivated with minimal systemic haemodynamic effects.

iNO is approved for treatment for pulmonary hypertension and to support right ventricular function in newborn infants. Numerous, well-conducted, randomised, controlled trials have demonstrated benefits in term infants with hypoxic respiratory failure when ventilation and resuscitation measures alone were not enough. The use of iNO for pulmonary hypertension can improve oxygenation and reduce the need for ECMO, but does not alter mortality and long-term neurodevelopmental outcomes. Due to the mixed and dynamic nature of PH, up to 40% of infants with hypoxaemic respiratory failure can have either no response or only a transient response to iNO.

The routine use of iNO in preterm infants with hypoxaemic respiratory failure and infants with congenital diaphragmatic hernia (CDH) has not shown a reduction in mortality or morbidity. However, targeted use of iNO in certain pathophysiological situations can improve outcomes in these specific situations and will be discussed separately.

**Treatment of pulmonary hypertension in the newborn, main pillars**

The primary treatment for PH is, if possible, to treat the underlying cause. For example, appropriate surfactant therapy for RDS, drainage of moderate to large pneumothoraces, antibiotics for sepsis etc. It is highly desirable to establish arterial access and obtain an arterial blood gas (ABG) before starting treatment for PH. This should, preferably, be post-ductal (umbilical, foot or left hand), but any arterial line is better than none. The main pillars of treatment for PH are:
A. Optimize lung volumes

Before starting iNO, mean airway pressure (MAP) should be adjusted to provide adequate lung inflation which must be confirmed by chest X-ray. In many, but not all, situations, this might mean using high-frequency oscillatory ventilation (HFOV) particularly if the patient also has high PaCO₂ and parenchymal lung disease. MAP can also be optimized on conventional ventilation by appropriate adjustments to PEEP and inspiratory time. Lung recruitment in lung parenchymal disease and substantial PH can be difficult, as oxygenation parameters used to guide recruitment are complicated by intra and extra-pulmonary shunting.

**Targets for PaO₂ and SpO₂**

Animal studies have shown that PVR rises steeply if PaO₂ falls below 50 mmHg, but only decreases gradually if PaO₂ is above 60 mmHg. The lowest PVR could be maintained with pre-ductal peripheral SpO₂ in the 90% to 97% range; with pre-ductal PaO₂ between 60 and 80 mmHg. Thus, normal saturation targets can be maintained for newborns with PH (i.e. SpO₂ between 90 and 94%).

**Targets for PaCO₂ and pH**

The physiological response to increased PaCO₂ is pulmonary vasodilatation. However, the accompanying acidosis is a stronger trigger for pulmonary vasoconstriction. Hence, the focus for pulmonary hypertension treatment should be on pH, not PaCO₂. If possible, target a pH between 7.30 to 7.40 and not less than 7.25. Permissive hypercapnia is allowed; to minimise ventilator associated lung damage.

**Targets for spontaneous breathing**

In most cases, some spontaneous breathing motion is beneficial for the cardiorespiratory balance. However, especially in distressed and agitated patients, asynchronous spontaneous breathing can also be a significant contributor to a high PVR. Optimize sedation to ensure the patient is as comfortable as possible. Routine paralysis is not recommended, but sometimes muscle relaxants are needed to optimise ventilation and sedation. Be aware of side effects of the medications used. Sedation with narcotics and/or benzodiazepines can reduce systemic vascular resistance and thus lower systemic blood pressure. Paralysis can alter venous capacitance and venous return.

B. Lower pulmonary arterial pressure

There are various pharmacological preparations that can lower PAP. This guideline will primarily focus on the use of iNO to help lower pulmonary.

**Starting iNO**

The indication to start iNO is:

- Any infant ≥ 34 week gestation with severe respiratory failure
  - Defined as PaO₂ < 100 mmHg on FiO₂ > 0.8 and/or an Oxygenation Index (OI) between 15 and 25
Inhaled nitric oxide (iNO) therapy in NICU for Pulmonary Hypertension JHCH_NICU_12.08

Start at 20 ppm in a term infant. Consider starting iNO at 10 ppm in preterm infants (see below).

Try not to make any ventilatory/FiO₂ changes or disconnect infant from ventilator for at least 30 minutes after iNO has been started (unless a positive response is already established) to be able to confirm patient’s response to treatment. In cases of no response, it might be appropriate to continue ‘trial’ of therapy to a maximum of 1 hour.

Assessing response

The iNO responsiveness must be assessed within 30 minutes of initiation. It is preferable to obtain another ABG and establish response using PaO₂ but in cases where arterial access is not available, post-ductal SpO₂ may be used.

Positive response:
- Rise in post-ductal PaO₂ of ≥ 20 mmHg or ≥ SpO₂ by 10% or able to drop FiO₂ by at least 0.2
- Significant reduction in R-to-L shunt and improved left ventricular filling on echocardiography

Partial response:
- Rise in post-ductal PaO₂ by 10–12 mmHg or SpO₂ between 5 and 10% or able to drop FiO₂ by 0.1–0.2
- Reduction in R-L shunt on echocardiography

Negative response:
- No change or minimal rise in post-ductal PaO₂ (≤ 10 mmHg) or SpO₂ (< 5%) or only able to drop FiO₂ by < 0.1
- No reduction in R-L shunt on echocardiography

If there is a positive or partial response, continue iNO and subsequently wean according to the schedule below. If there is no significant improvement in oxygenation after 30 minutes of treatment with 20 ppm of iNO (negative response) then iNO therapy should be discontinued and details of lack of response documented. There is no need to wean iNO in this situation. It is important that during the trial period of iNO, no additional ventilator changes are made as it can make interpretation of ‘response to iNO therapy’ difficult. Be aware that, if the iNO trial was longer than 30 minutes, the patient might experience deterioration in oxygenation in spite of a negative response. This deterioration is usually transient (from 30 minutes to 4 hours) and is secondary to suppression of endogenous NO production. This should NOT be considered as an indication for restarting iNO therapy if there was a confirmed negative response.

Weaning iNO

After a sustained positive response is established and oxygenation improved, gradually but frequently wean FiO₂ to minimum required concentration (generally < 0.4). Once FiO₂ has been weaned to a clinically appropriate concentration, it is desirable to maintain iNO for a period of 6–12 hours. This is to ensure a period of stability is provided, following which the weaning process can start based on the infant’s FiO₂ requirement.
Wean iNO by 5 ppm every 2 hours until down to 5 ppm; leave on 5 ppm for 2 hours; then wean by 1 ppm every 2 hours to zero.

Discontinue weaning if, at any point, one or more of the following occur:

- FiO₂ rises by > 0.2
- Pre-ductal saturation returns to > 10% higher than post-ductal

If weaning had to be discontinued, then increase iNO by one step at a time until infant returns to pre-deterioration status and then leave for at least 12 hours before recommencing weaning. This time, the weaning strategy should be slower than the earlier attempt and should be decided on an individual basis by the attending team.

Be aware that some infants may still develop a transient hypoxaemia once iNO therapy is discontinued. This is due to suppression of endogenous NO by exogenous therapy. The hypoxaemia is usually moderate (needing increase in FiO₂ by 0.2) and short-lasting (up to an hour). This should not be a reason to restart iNO therapy but should be treated by increasing FiO₂.

**Monitoring during treatment with iNO**

Nitrogen dioxide is continuously monitored and concentration displayed on the delivery system. Aim should be to ensure concentrations below 2 ppm.

Significant methaemoglobinaemia has never been reported with the use of iNO at ≤ 20 ppm. If Met Hb level is ≥ 3%, then medical team should be notified and weaning of iNO should be considered. Subsequent levels should be checked every 24 hours. A Met Hb level ≥ 5% should prompt discontinuation of iNO.

In any infant with hypoxaemic respiratory failure, the possibility of structural heart defect should be strongly considered if one or more of the following occurs in addition to iNO non-responsiveness:

- Lack of symptoms of respiratory distress
- Lack of lability, haemodynamic stability in spite of extreme hypoxaemia of prolonged duration
- Pre-ductal SpO₂ lower than post-ductal
- Presence of a heart murmur or abnormal cardiac silhouette on CXR

If iNO therapy is needed for longer than 7 days, an alternative diagnosis should be considered (e.g. capillary alveolar dysplasia, surfactant deficiency).

**C. Supporting cardiovascular function**

The main haemodynamic feature of PH is increased PAP. However, this physiological state is not different from the fetal situation. With persistent hypoxia, the increased PAP and thus afterload for the RV will eventually lead to RV dysfunction. Reduced pulmonary blood flow will lead to reduced preload for the left LV and lead to systemic hypoperfusion and shock.
PH is a dynamic process, and the degree of PH does not correlate well with the degree of right ventricular dysfunction or clinical outcomes.

Repeat assessments of the systemic arterial blood pressure, estimates of pulmonary arterial pressure, shunt and shunt direction and right and left ventricular function are needed to target cardiovascular treatments.

Cardiovascular support during PH and iNO treatment should be guided by the systemic arterial blood pressure (SAP), estimates of pulmonary arterial pressure and the PAP:SAP ratio.

Significant systemic hypotension should be corrected before iNO is started.

Medications that increase the PAP:SAP ratio (e.g. dopamine) should be avoided.

There is no evidence that increasing the systemic blood pressure to ‘supranormal’ levels improves outcomes. Pursuing this approach often leads to catecholamine overload (> 2 cardiovascular medications running simultaneously) which can lead to tachycardia and increased PAP:SAP ratio and should be avoided.

<table>
<thead>
<tr>
<th>Cardiovascular support agent</th>
<th>Expected actions</th>
<th>Comments</th>
<th>Physiological target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>Improves cardiac input</td>
<td></td>
<td>Low preload, collapsed systemic veins</td>
</tr>
<tr>
<td>Dopamine</td>
<td>Pressor</td>
<td>Increases afterload</td>
<td>Systemic hypotension, normal blood flow</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increases PAP:SAP ratio</td>
<td></td>
</tr>
<tr>
<td>Dobutamine</td>
<td>Pressor, improves contractility</td>
<td>Tachycardia</td>
<td>Low contractility, low blood flow, PH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>May decrease PAP:SAP ratio</td>
<td></td>
</tr>
<tr>
<td>Adrenaline (epinephrine)</td>
<td>Pressor, improves contractility</td>
<td>Tachycardia</td>
<td>Low contractility, low blood flow, systemic hypotension</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Beta-adrenergic stimulation with hyperglycaemia and increased lactate May decrease PAP:SAP ratio</td>
<td></td>
</tr>
</tbody>
</table>
Inhaled nitric oxide (iNO) therapy in NICU for Pulmonary Hypertension

<table>
<thead>
<tr>
<th>medication</th>
<th>description</th>
<th>effect</th>
<th>side effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noradrenaline (norepinephrine)</td>
<td>Pressor, improves contractility</td>
<td>Increases afterload</td>
<td>Low contractility, systemic hypotension, PH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Decreases PAP:SAP ratio</td>
<td></td>
</tr>
<tr>
<td>Milrinone</td>
<td>Phosphodiesterase inhibitor, improves contractility</td>
<td>Reduces afterload</td>
<td>Low contractility, low blood flow, high afterload, PH with right ventricular failure</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tachycardia, systemic hypotension</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>May exacerbate right-to-left shunting</td>
<td></td>
</tr>
<tr>
<td>Vasopressin</td>
<td>Neurohormone, increases peripheral vascular resistance</td>
<td>May decrease PAP:SAP ratio</td>
<td>Systemic hypotension, PH</td>
</tr>
<tr>
<td>Alprostadil</td>
<td>Prostaglandin E2, opening of the ductus arteriosus (DA)</td>
<td>May cause systemic hypotension</td>
<td>High PAP with right ventricular failure due to closing of the DA</td>
</tr>
<tr>
<td>Sildenafil</td>
<td>Phosphodiesterase type 5 inhibitor, reduces PAP</td>
<td>Oral, slow onset of action</td>
<td>High PAP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>May cause systemic hypotension</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone</td>
<td>Corticosteroid</td>
<td>Increases SAP</td>
<td>Inotropic-resistant, systemic hypotension</td>
</tr>
</tbody>
</table>

Specific clinical situations and other considerations for iNO use

**Preterm infants with hypoxic respiratory failure**

Trials of prophylactic or early (within first 2 postnatal days) rescue use of iNO to prevent chronic lung disease (CLD), decrease mortality & improve long-term neurodevelopmental outcomes have yielded conflicting results, with most showing no improvement in morbidity or mortality. It must be remembered that these trials did not evaluate infants for presence of PPHN prior to inclusion. It is possible that many patients included in these trials had exclusively parenchymal lung disease which, for obvious reasons, would fail to respond to iNO. One trial in preterm infants, only included patients with a higher likelihood of PH (infants with oligohydramnios and prolonged premature rupture of membranes) and demonstrated improved survival and CLD rates. When used, iNO exposure must be kept to lowest duration possible as there are unresolved concerns of possible adverse long-term effects associated with use of iNO in preterm infants.

Inhaled NO should not routinely be used in preterm infants with hypoxic respiratory failure.

In preterm infants with evidence of lung hypoplasia and pulmonary hypertension due to prolonged PPROM, start iNO 10–20 ppm early and monitor response. Obtain an echocardiogram before treatment or as soon as possible after initiation.
In preterm infants with hypoxic respiratory failure due to other reasons, it is not recommended to start iNO without documenting significant pulmonary hypertension on echocardiography.

In preterm infants with severe CLD and associated significant PH documented on echocardiogram, iNO may be appropriate when clear clinical goals are defined prior to initiation of iNO therapy (for example, acute stabilisation while infant is being started on intravenous steroids; therapy for a predefined period in an attempt to reverse pulmonary hypertension).

**Infants with congenital diaphragmatic hernia (CDH)**

Inhaled NO treatment in infants with CHD did not improve morbidity or mortality nor reduce the need for ECMO. However, iNO therapy is commonly started in most infants with CDH and PH. CDH affects not only the pulmonary vascular system, but is often associated with reduced left ventricular size and altered function. Pulmonary vasodilatation in the setting of increased pulmonary venous pressure due to poor left ventricular function will lead to pulmonary congestion and will worsen pulmonary function.

Inhaled NO should be used cautiously in infants with CDH and it is recommend to start only after echocardiography has documented a reasonable LV size, acceptable LV function and the presence of significant pulmonary hypertension or right ventricular dysfunction.
Inhaled nitric oxide (iNO) therapy in NICU for Pulmonary Hypertension JHCH_NICU_12.08

References


Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD000399


Logan JW, Cotten CM, Goldberg RN, Clark RH. Mechanical ventilation strategies in the management of congenital diaphragmatic hernia. Semin Pediatr Surg. 2007 May;16(2):115-25


**Section 2**

**INOmax DS<sub>r</sub> Plus setup and testing**  Top

The INOmax DS<sub>r</sub> Plus system is currently used to deliver iNO to the infant. It delivers nitric oxide gas into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of NO, as set by the user, to the patient throughout the inspired breath whilst tracking the ventilator waveform via the injector module.

The INOmax DS<sub>r</sub> Plus also includes an INOblender. The INOblender is used independently of the INOmax DS<sub>r</sub> Plus. It allows NO delivery via the Neopuff or Laerdal bag.

**Before you begin—Some points to be aware of:**

The INOmax DS<sub>r</sub> Plus has a battery life of 6 hours. The back-up switch is provided in case of INOmax DS<sub>r</sub> Plus circuit power board failure. The backup system will need to be activated to ensure a continued supply of NO to the infant until an alternate INOmax DS<sub>r</sub> Plus can be provided.

The INOmax DS<sub>r</sub> Plus relies on infrared (IR) technology to detect the presence of the nitric oxide (INOmax) cylinder. The infrared detection device can be affected by bright lights and anything that covers the top of the cylinder dial.

---

**DO NOT** COVER THE CYLINDER DIAL and keep it away from BRIGHT LIGHTS

---

**Cylinder Valve Closed**

— symbol indicates meter is off

Displays dashes indicating the cylinder is closed

Displays cumulative cylinder time

**REMEMBER**

NITRIC OXIDE IS VERY EXPENSIVE!!

PLEASE ENSURE CYLINDERS ARE TURNED OFF WHEN NOT IN USE
• Keep plugged in and connected to power at all times
• Determine when the last ‘pre-use’ procedure check was completed. It must be performed 12th hourly.
• The injector module must have the arrow pointing in the direction of the gas flow from the ventilator (or CPAP circuit) towards the patient.
• Touch screen wizard technology assists with the pre-use procedure
• Low calibration will occur automatically when in use. The system delivers the set parts per million (ppm) of NO; however, during calibration the values will read as 0.
• **The injector module must be placed between the ventilator inspiratory gas outlet and the HFOV tubing**

**ALERT**

*If the backup system is switched on whilst the INOmax DS\textsubscript{IR} Plus is running, it will deliver 250 mL/minute of NO in addition to the prescribed dose of NO.*

*A high priority alarm will be present*

INOmax DS\textsubscript{IR} Plus setup

Setting up of the INOmax DS\textsubscript{IR} Plus is a staged process with which all staff should be familiar.

**Note:** The technical assistants prepare the INOmax DS\textsubscript{IR} Plus setup to be ready for bedside use. However, it is the nurse who is responsible for ensuring that the equipment is in correct and working order.

If the INOmax DS\textsubscript{IR} Plus is not set up ready for testing, the following description takes you through the process.

1. Sample T-piece
2. Blue corrugated hose
3. Injector module (note direction of arrow towards sample T-piece)
4. White straight connector
5. Grey adaptor
6. Patient gas sample line
7. Water filter cartridge
8. Clear injection tubing
9. Grey electrical cable (ensure red dots are aligned)
10. Green oxygen tubing
11. Inspiratory limb elbow (ventilator attachment—may be grey or green)
12. Sample T-piece connector to attach to inspiratory limb the ventilator at patient end.
Inhaled nitric oxide (iNO) therapy in NICU for Pulmonary Hypertension JHCH_NICU_12.08

- Plug in power cord and verify green AC power light is ON
- Attach the DUAL oxygen outlet to the wall oxygen
- Attach the free end of the green oxygen tubing to the dual oxygen wall outlet
- Check date and dose of gas cylinder to be used. The cylinders contain 800 parts per million (ppm) nitric oxide gas
- Remove INOMAX regulator and pressure gauge from back of cart and verify that the white Kel-F tip is in place and not damaged. (The regulator may already be inserted into the INOMAX treatment cylinder, if so there is no need to remove it)
- Connect high pressure regulator to INOMAX cylinder
Inhaled nitric oxide (iNO) therapy in NICU for Pulmonary Hypertension JHCH_NICU_12.08

**Back of INOmax DS\textsubscript{IR} Plus**—showing infrared cable (IR), INOblender hose, regulator hose, INOblender O\textsubscript{2} hose and purge port; all of which are labelled in red.

- Connect regulator hose to the inlet on the back of the device
- Note that each gas cylinder has an INOMAX regulator hose. Only the hose attached to the cylinder in use needs to be inserted into the back of the INOmax DS\textsubscript{IR} Plus
- Check grey INOblender hose is in situ
- Check black infrared cable is in situ
- Check oxygen supply hose is connected to the INOblender

**Setup**

1. Ensure the water trap bottle and water separator container are connected.
2. Connect the sample line to the sample line inlet port on the front of the INOmax DS\textsubscript{IR}.

**INOmax DS\textsubscript{IR} connections**

- Remove any protective caps from the connectors and ports on the INOmax DS\textsubscript{IR}.
- Ensure the INOmax DS\textsubscript{IR} is on a flat surface or is fixed securely to a cart or transport sled.

**INOblender Oxygen hose**

- Infrared (IR) Cable—DO NOT REMOVE
- INOblender Hose—DO NOT REMOVE
- Purge port
- Regulator Hose
Inhaled nitric oxide (iNO) therapy in NICU for Pulmonary Hypertension JHCH_NICU_12.08

- Ensure the water trap and water separation cartridge are in place as shown above
- Ensure the patient gas sample line is connected to the port above the water trap bottle
- Ensure the injector module cable and electrical cable are in place as shown below
- Ensure the backup switch is OFF. (Dial set at 0 when in the off position)

Front of machine

- Ensure INOblender dose setting dial is OFF. (Dial set at 0 when in the off position)
- Turn the INOmax DSir Plus delivery system ON (on/off switch located at the back of the machine)—a splash screen will appear followed by an Ikaria test screen which may take a minute or so. The speaker will sound followed by the main screen.
- Press the patient-head icon on the screen and type in ‘Training’, this is important as the NICU doesn’t get charged for nitric oxide used for training purposes.
- Low calibration will automatically begin and complete when the system is turned on.

INOmax DSir Plus Pre-use tests

Step 1

High-pressure leak test

- Make sure INOMAX cylinder icon is present
- Open/close INOMAX cylinder valve (verify cylinder is >500 psi)
- Wait 30 seconds and ensure there is no pressure drop
- If no pressure decrease observed, the high pressure leak test is complete
Inhaled nitric oxide (iNO) therapy in NICU for Pulmonary Hypertension JHCH_NICU_12.08

Step 2
Manual purge and alarm verification
Most commonly, an automated purge is performed by using the touch screen wizard. If a manual purge is required, then the information below shows how to do this.

Complete pre-use procedure setup

- Press CANCEL to exit pre-use wizard
- Ensure INOMAX cylinder valve is closed
- Connect green oxygen tubing to wall oxygen
- Set O₂ flow meter to 10 L/min
- Set the INOMAX dose to 40 ppm (‘Cylinder Valve Closed’ alarm will occur and cylinder pressure should drop to 0)
- Purge is complete when ‘Low Cylinder Pressure’ alarm activates
- Open cylinder valve
- Turn INOMAX dose to zero
  (Note: The ‘Set Dose is Zero, Close cylinder Valve’ indicator will appear; at this point do not close the cylinder valve. Please ignore this indicator at all times during the pre-use procedure)

Automated purge
- Ensure injector module is **not attached** to a patient circuit
- Press next button to commence purge
- Alarm will sound
- Automated purge complete
- Open the cylinder valve

Step 3
Backup delivery test
- Ensure pre-use setup connectors and tubing are set up correctly
  *If uncertain press ‘show diagram’ button for an immediate image and ensure the injector module arrow is in the direction of the gas flow*
- Set wall oxygen to 10 litres/minute
- Turn integrated backup on (250 mL/minute)
- Verify backup alarm occurs
- Allow values to stabilise NO₂ < 1.0 ppm, NO 14–26 ppm
- Backup delivery test complete; turn backup off
Step 4
Performance test
- Verify oxygen flow set at 10 litres/minute
- Press next button to automatically set dose to 40 ppm
- Verify monitor values
- NO₂ <1.5 ppm, NO 35–45 ppm and O₂ 92–98%
- Performance test complete

Step 5
INOblender test
- Turn O₂ flow meter off and remove green oxygen tubing from flow meter and attach to front of INOblender
- Remove injector module from pre-use setup and re-connect connectors
- Set INOblender to 40 ppm of NO and O₂ to 10 litres/minute
- Allow values to stabilise with NO 32–48 ppm
- Turn NO dose and flow to off
- INOblender test is complete

If the NO isn’t going to be used within 10 minutes then
- Close cylinder valve until you get the --- symbol
  *Note the disappearance of the green head of the cylinder on the screen which confirms that the cylinder is off*
- Depressurise the regulator hose via the labelled purge port at the back of the machine
- Return the injector module to the setup as for pre-use procedure setup
- No need to depressurise if the INOmax DSᵢₑ Plus is to be used immediately
- If the INOmax DSᵢₑ Plus has been checked and not depressurised within 10 minutes repeat automated or manual purge procedure

**The INOMAX DSᵢₑ Plus if not used, must have the pre-use procedure repeated 12 hourly**

General information
- Patient information can be filled in at any time and is useful for data collection; the system requires rebooting to remove patient data
- High-range calibration is completed every 30 days and can be done whilst on the patient
- During calibration, monitoring values show zero and grey bars appear under numeric windows as the machine calibrates to air
- A low-range calibration is automatic and will occur at setup and then repeat automatically dependent on the use of the nitric oxide.
Inhaled nitric oxide (iNO) therapy in NICU for Pulmonary Hypertension JHCH_NICU_12.08

- Cancelling the low-range calibration is possible; once cancelled, calibration will automatically occur again in 15 minutes.
- Sample error may occur; the most common reason is an issue with the water filter which needs to be replaced. Be aware that the NO dose will read zero, however the set dose is still being delivered while the cartridge is out.
- Emptying the water trap requires the use of PPE. Be aware that the NO dose will read zero, however the set dose is still being delivered while the water trap is disconnected. Empty the water trap contents into a kidney dish and clean dish after use.
- The monitor and delivery system of the INOmax DSIR Plus are separate, therefore, if the monitor powers out, NO will continue to be delivered even though it is not indicating so on the monitor screen.
- Backup is independent of power. There is a 30-minute alarm.
- Flow sensor calculates the dilution of 800 ppm to be delivered based on the flow from the ventilator.
- NO is directed to the ventilator at 250 mL/minute (800 ppm cylinder) when backup switch turned on. When the ventilator flow is 10 litres/minute, the baby will be receiving 20 ppm of NO. If there is a pressure leak and low pressure, check INOblender or backup switch are not turned on.
- Yellow is a low-priority alarm.
- Red is a high-priority alarm.
- If the low-pressure alarm warning is signalling you really have no gas! Always change when at 500 psi.
- Alarm help key available to direct you through steps to fix a problem.
- Only one regulator hose can be plugged in at any time as two can cause a leak of NO.
- Alarm history can store 2000 entries and all is deleted when INOmax DSIR Plus rebooted.
- Alarm limits default to 50 above and below what is being delivered and are automatically confirmed when initial dose set. Any other dose changes require the high and low alarms to be altered manually.
- Expiratory date on cylinder is underneath bar code, machine will not deliver if expired (first day of the month is the expiry date not the last day).
- Sample T-piece should be approximately 15 cm from the ETT. If closer than this, both the inspiratory and expiratory gases will be sampled possibly resulting in an under-reading i.e. set dose of 20 ppm may read 16 ppm.
- A diagram is available within the setup menu to facilitate the correct setup of the equipment.
- Time can be changed via the settings button.
Section 3

Changing the NO cylinder

Step 1

- Change the INOMAX cylinder when the pressure gauge shows a pressure of **200 psi or less**
- Crack open the new cylinder
- Remove the INOMAX regulator currently not in use from the back of the cart; verify the white Kel-F tip on the regulator is in place and not damaged
- Connect this INOMAX regulator to the new INOMAX treatment cylinder
- **DO NOT** insert the INOMAX grey regulator hose into the back of the INOmax DSr Plus at this point

Step 2

- Open and close the INOMAX cylinder
- Ensure the cylinder shows more than 200 psi on the gauge
- Ensure you are using an INOMAX cylinder that is 800 ppm and check expiry date
- Watch the pressure gauge for 30 seconds to check for leakage

Step 3

Take the grey regulator hose which is not currently in use and insert into the purge port. Push firmly
- There will be a sound of escaping gas and a degree of pressure is felt as the hose and gauge are depressurised
- Observe pressure gauge needle drop to ZERO

Step 4

- Remove the grey regulator hose from the purge port and insert into the gas inlet at the back of the INOmax DSr Plus
- Turn on the new cylinder. This may activate the ‘Two cylinders open’ alarm until the empty cylinder is closed
- Turn off the old cylinder
- Remove the grey regulator pressure hose which has been in use on the old cylinder from the back of the INOmax DSr Plus
- **Inform the TAs that the cylinder is empty and label as empty**
- Remove cylinder from bedside using gas trolley
- Replace with new cylinder if and when possible
Section 4
Management

Management of an infant receiving iNO

Infants receiving INO are extremely fragile and require skilled nursing and medical management/care to support their cardio-respiratory system. Please refer to:

- Assisted Ventilation of the newborn 5-5.1.4(a)
- High Frequency Oscillatory Ventilation (HFOV) 5-5.1.4(b)
- Hypotension and poor circulation in neonates JHCH_NICU_13.04
- Endotracheal Tube (ETT) Suction in NICU 5-5.1.9
- Transcutaneous Oxygen /carbon dioxide Monitoring JHCH_NICU 12.05
- Assessment and Management of Pain in the Neonate JHCH_NICU 03.04

Monitoring and precautions when using iNO therapy

- Infants requiring increasing iNO are very sensitive to changes in iNO delivery
- The half-life of NO is 5 seconds; abrupt disconnections or interruptions to the circuit should be avoided as it may lead to increased pulmonary vascular resistance and worsening oxygenation
- Minimal handling, as these babies are often hemodynamically unstable; they may require pacing through cares and cares may be required 8 to 12th hourly
- Adapt the environment for the baby; provide a noise and light-reduced setting as these infants are also highly sensitive to noxious stimuli
- NO is an inhibitor of platelet function, therefore, caution is needed when an infant has thrombocytopenia or other bleeding irregularities
- Nitrogen dioxide may cause airway inflammation and damage to lung tissues and should not exceed 2 ppm
- Arterial blood gas analysis is performed PRN and requires consultation between nurse and medical team
- Methaemoglobin levels are dose dependent and should be maintained at < 3%; levels of 3–5% are rare at doses ≤ 20 ppm; however, if 5%, neonatologist must be informed and nitric oxide treatment ceased³, 4.
- FiO₂ is monitored from the INOmax DS₉ Plus, not the ventilator
- Oxygen index calculation
- Transcutaneous carbon dioxide monitoring and hourly documentation
- Pre- and post-ductal saturation monitoring and hourly documentation
- Continuous heart rate and arterial blood pressure monitoring and hourly documentation
- Check with in-charge MO what is an acceptable systolic and mean arterial pressure for the baby
- Ventilation and humidity settings and hourly documentation
- Cardiac ECHO is recommended prior to commencing INO to assess pulmonary pressures and haemodynamic status of the infant, assist in establishing the diagnosis, review left and right ventricular function and optimise circulatory support
- Before attachment to the infant, ensure correct setup procedure has occurred
• Ensure that ventilator trigger setting is accurate as the commencement of NO can affect trigger sensitivity
• Inhaled NO must be prescribed in ppm on the stat medication chart, signed by two staff and recharted daily
• Document iNO and NO₂ levels hourly on the nursing flow chart
• The INOblender should be set at 10 litres/min when in use
• Match INOblender dose to treatment dose
• Check PIP and PEEP of the Neopuff are at desired levels prior to attachment to baby
• Prior to use, purge NO₂ from the Neopuff circuit by running system for 10 seconds prior to connection to baby
• Empty water trap into yellow kidney dish when water observed in the trap. Empty at the bedside as the NO concentration can be affected during this procedure (PPE must be worn)
• Inhaled NO should be weaned gradually once the desired effect has been achieved; see weaning in section 1. When iNO ceased, and not re-used within 10 minutes, remove from the ventilator circuit and depressurise
• Keep parents informed of their infants’ condition
Appendices

Appendix 1  Connections and setup for iNO via Fabian Ventilator
Appendix 2  Attachment to T-piece flow driver (Neopuff™)
Appendix 3  Connections and setup for iNO via HP circuit
Appendix 4  Connection to Fisher & Paykel™ bubble CPAP
Appendix 5  Manual Pre-use Checkout
Appendix 6  INOmax DS\textsubscript{IR} Plus Handover Circuit Checklist
Appendix 1 Connections and setup for iNO via Fabian Ventilator

Two connectors—an inspiratory limb sampling port and an inspiratory limb elbow—are required to attach the INOmax DSIR Plus to the Fabian; these are kept with the INOmax DSIR Plus

- Remove clear sample T-tubing from the plastic sample T-piece connector (which is next to the blue corrugated tubing)
- Attach clear sample tubing to inspiratory limb sampling port
- The plastic sample T-piece connector and blue corrugated tubing are no longer required
- Attach green or clear elbow to injector module

If the system has previously been depressurised, turn the cylinder on now

Attaching the INOmax DSIR Plus to the Fabian ventilator
Sample T-tubing must face upwards once attached to the circuit to prevent water collection.

SET iNO dose as per medical officer. Press touchscreen dial, set dose with control wheel and press the control wheel to confirm.
Appendix 2 Attachment to T-piece flow driver (Neopuff™)

Attach grey adapter and oxygen tubing to the Neopuff, as shown

• To test the Neopuff™, set INOblender dose to 20 ppm and flow to 10 litres/minute
• Set Neopuff pressures as per infant’s condition
• Turn INOblender dose and flow off
• If Neopuff™ is required, match INOblender dose to treatment dose and purge the system by running a flow of 10 litres/minute for 10 seconds prior to connection to the baby
Appendix 3 Connections & setup for iNO via HP circuit

Nitric oxide sampling port attached to T-piece and placed in blue inspiratory tubing as shown
Inhaled nitric oxide (iNO) therapy in NICU for Pulmonary Hypertension JHCH_NICU_12.08

Appendix 4.

Connection to the Fisher & Paykel Bubble CPAP

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Oxygen source</td>
<td>10. Inspiratory limb sampling port</td>
<td></td>
</tr>
<tr>
<td>4 &amp; 5. Green adapter</td>
<td>13. NO/N&lt;sub&gt;2&lt;/sub&gt; injector tube</td>
<td></td>
</tr>
<tr>
<td>7. Temperature probe</td>
<td>15. INOmax DS&lt;sub&gt;IR&lt;/sub&gt; Plus</td>
<td></td>
</tr>
<tr>
<td>9. Bubble CPAP generator</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

from INOmax DS<sub>IR</sub> ® Plus Pocket Guide (2012)
Appendix 5

Manual pre-use checkout
9/ Appendix

Manual Pre-Use Checkout

The following instructions are provided for when the on-screen pre-use wizard is not used.

1. Turn device ON, low calibration will begin and complete (Continue with steps 2-4 while calibration completes)

2. Initial Connections:
   Confirm attachment of the following:
   a. Water separator cartridge, water bottle, and patient gas sample line in place
   b. Injector module cable and tubing are connected
   c. Plug in power cord and verify AC power light is ON
   d. Regulator to INOMAX cylinder
   e. Regulator hose to INOMAX DSIR inlet
   f. INOblender hose connected and white lock in place
   g. Oxygen source (50 psig) to back of INOblender
   h. IR cable in place

3. Assemble pre-use set-up connectors (see Figure 9-1). Do Not turn on O₂ flowmeter yet.

4. High Pressure Leak Test:
   Open/close INOMAX cylinder valve
   a. Verify, at least 34.5 bar (500 psig) cylinder pressure
   b. Verify, no decrease in cylinder pressure for 30 seconds
5. **Manual Purge/Alarm Verification:**
   a. Press CANCEL to exit pre-use wizard (low calibration should be complete to continue).
   b. Verify INOMAX cylinder valve is closed.
   c. Set O₂ flowmeter to 10 L/min.
   d. Purge INOMax DS<sub>iR</sub>.
      - Set the INOMAX dose based on cylinder concentration:

      | Cylinder Concentration (ppm) | 800 | 400 |
      |-------------------------------|-----|-----|
      | Set Dose (ppm)                | 40  | 20  |

   "Cylinder Valve Closed" alarm will occur.
   - Continue until cylinder gauge pressure drops to 0 psig.
   - Measured NO<sub>₂</sub> will increase and then decrease as NO<sub>₂</sub> is purged from the system.
   - "Low Cylinder Pressure" alarm will occur.

   e. Turn INOMAX dose to zero.
   f. Open INOMAX cylinder valve.

6. **Integrated Pneumatic Backup Test:**
   a. Verify pre-use assembly flowmeter set to 10 L/min.
   b. Turn INOMax DS<sub>iR</sub> backup switch ON.
   c. Allow monitored values to stabilize.
   d. Verify measured values based on cylinder concentration:

      | Cylinder Concentration (ppm) | 800 | 400 |
      |-------------------------------|-----|-----|
      | NO (ppm)                      | 14 - 28 | 7 - 13 |
      | NO<sub>₂</sub> (ppm)          | ≤ 1,0  | ≤ 1,0  |

   e. Turn backup switch OFF.
7. Performance Test:
   a. Verify O₂ flowmeter is set to 10 L/min
   b. Set INOMAX dose based on cylinder concentration:
      | Cylinder Concentration (ppm) | 800 | 400 |
      | Set Dose (ppm)               | 40  | 20  |
   c. Verify monitored values
      | Cylinder Concentration (ppm) | 800 ppm | 400 ppm |
      | Set Dose (ppm)               | 40    | 20    |
      | Acceptable NO Value (ppm)    | 35 - 45 | 17 - 23 |
      | Acceptable NO₂ Value (ppm)   | < 1.5  | < 1   |
      | Acceptable FIO₂ (%)          | 96 ± 3 | 96 ± 3 |
   d. Set INOMAX dose to 0 ppm
      - "Set Dose is Zero, Please Close Cylinder Valve" reminder will appear; DO NOT close cylinder valve at this time, dismiss reminder.
   e. Turn oxygen flowmeter OFF

8. INOblender Test:
   a. Remove injector module from pre-use assembly and reconnect tubing
   b. Remove O₂ tubing from flowmeter and attach to INOblender outlet
   c. Set INOblender flow to 10 L/min, INOMAX dose to:
      | Cylinder Concentration (ppm) | 800 | 400 |
      | Set Dose (ppm)               | 40  | 20  |
   d. Verify monitored values on the INOMAX DSIR Plus
      | Cylinder Concentration (ppm) | 800 | 400 |
      | Acceptable NO Value (ppm)    | 32 - 48 | 16 - 24 |
   e. Set INOblender dose and flow to 0
Appendix 6 Handover Circuit Check List

**INOMax DS IR Plus**

**HANDOVER CIRCUIT CHECK LIST**

- Doctor's prescription vs set dose
- Set dose NO vs monitored dose NO
- Monitored dose of NO2 (<3ppm)
- Position of injector module
  - Direction of arrow = direction of ventilator flow
  - Dry side of the humidifier between ventilator and humidifier inlet
  - Need for one-way valve – position of valve
- Position of sample tee
  - Inspiratory limb
- INOblender set up correctly and attached to resuscitation bag/Neopuff
- Check pressure gauge on regulator (consider cylinder change if psi < 500)
References


Inhaled nitric oxide (iNO) therapy in NICU for Pulmonary Hypertension JHCH_NICU_12.08

Developed by: Vivienne Whitehead CNE NICU
Paul Colelough (Technical Support Officer TSO) NICU
Dr Koert de Waal Neonatologist NICU

Updated by: Vivienne Whitehead CNE NICU
Dr Koert de Waal Neonatologist NICU

Reviewed by: Ruth Wootton CNS NICU
Danni Hanna RN NICU
Javeed Travadi Neonatologist NICU
Julie Gregory CNE NICU
Tracey Edwards TA NICU
Justine Parsons NE NICU
Ian Whyte Clinical Director of Toxicology Calvary Mater Hospital
Michelle Jenkins Senior Pharmacist, JHH

Approved by: NICU Management Committee 22/03/2017
JHCH CQ &PCC 28/03/2017

FEEDBACK Any feedback on this document should be sent to the Contact Officer listed on the front page.